Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab vs. Aflibercept for Post-Injection Inflammation in DME
NCT02363621Phase 2Completed
- Sponsor
- Arshad M. Khanani
- Start
- Jan 2015
- Primary completion
- Oct 2017
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of ranibizumab in diabetic macular edema (DME) (2 arms), sponsored by Arshad M. Khanani. Primary endpoint: Number of Participants With Intraocular Inflammation. Started Jan 2015; status: completed.
02
Drugs
ranibizumab
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT02363621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02363621.